Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 4/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25419641 | 0.84 | LMNA (0.54) | LMNAKITDDR1PDE4BPDE4D | |
| SCHEMBL3608804 | 0.84 | KIT (0.39) | LMNANAPRTKITDDR1PDE4B | |
| SCHEMBL30708693 | 0.83 | LMNA (0.53) | LMNAKITDDR1PDE4BPDE4D | |
| SCHEMBL18825814 | 0.80 | NTRK1 (0.47) | KITDDR1NTRK1DDR2 | |
| SCHEMBL27974407 | 0.76 | KIT (0.53) | KITDDR1DDR2 | |
| SCHEMBL31533194 | 0.76 | KIT (0.53) | KITDDR1DDR2 | |
| SCHEMBL25239960 | 0.75 | KIT (0.46) | KITDDR1DDR2 | |
| SCHEMBL7067259 | 0.75 | TP53 (0.43) | KITDDR1HCAR3GABRA1GABRB2 | |
| SCHEMBL12872518 | 0.73 | GAA (0.38) | KITDDR1GAAPDE4BPDE4D | |
| SCHEMBL3617962 | 0.73 | NAMPT (0.43) | ALKBH2HPGDSNAPRTP4HA1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079745-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008052964-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119320383-A | Nitrogen-containing heteroaryl compound, and preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-115650984-A | Preparation method of anagliptin | 江苏君若药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2010119284-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| EP-2203449-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2010-07-07 | — | — | EP | disclosed |
| EP-2197880-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | IMBACH PATRICIA | 2010-03-18 | — | — | US | disclosed |
| EP-2079745-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009047522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008052964-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | PRKCA, PRKACA, MAP3K19 | ALKBH2 4546/4885EGLN1 2147/4885HPGDS 820/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALKBH2 1609/4885EGLN1 1913/4885HPGDS 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.